切利尼布在超出ALK表达和突变的胆管癌中的治疗影响
Kyaw Zwar Myint1, Brinda Balasubramanian1,2, Simran Venkatraman1
1Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Pharmaceuticals (Basel, Switzerland)
|February 24, 2024
概括
利尼布有效地准胆管癌 (CCA) 细胞,提供了一种新的治疗途径. 这种向治疗也显示了与西斯普拉丁的协同作用,改善了这种难以治疗的癌症的结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 胆管癌 (CCA) 除了手术之外的治疗选择有限,标准化疗提供了不良的预后.
- 受体氨酸激酶 (RTKs) 在CCA中经常失调,代表了一个潜在的治疗标.
研究的目的:
- 通过选RTK抑制剂来确定CCA的有效向疗法.
- 在CCA模型中评估一种强有力的RTK抑制剂 - - 利尼布 (ceritinib) 的疗效和作用机制.
- 评估与西斯普拉丁联合使用的谢里替尼的协同作用潜力.
主要方法:
- 在KKU-M213 CCA细胞中选112个RTK抑制剂.
- 在体外细胞毒性测定 (MTT,克隆原性),免疫光,西部斑,和qRT-PCR.
- 使用球状体和异种移植模型进行体内研究.
- 使用ZIP协同成绩的药物相互作用分析.
主要成果:
- 在临床上相关的度下,切利尼尼对CCA细胞具有显著的细胞毒性,独立于ALK状态.
- 切利尼布抑制了PI3K/Akt/mTOR通路,并诱导了亡和自.
- 与谢里替尼和西斯普拉丁的联合治疗在降低CCA细胞活力方面表现出协同效应.
结论:
- 利尼布是治疗胆管癌 (CCA) 的有希望的治疗药物,在临床前模型中显示出有效性.
- 切利尼尼的机制涉及关键信号通路的调节和诱导细胞死亡.
- 结合治疗与谢里替尼和西斯普拉丁为改善CCA治疗结果提供了一个潜在的策略.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.7K
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
872
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
